国浩律师（济南）事务所 关于鲁商福瑞达医药股份有限公司 二〇二六年一月 鲁商福瑞达医药股份有限公司 2026 年第一次临时股东会之法律意见书 国浩律师（济南）事务所 关于鲁商福瑞达医药股份有限公司 2026 年第一次临时股东会之 法律意见书 致：鲁商福瑞达医药股份有限公司 国浩律师（济南）事务所（以下简称"本所"）接受鲁商福瑞达医药股份有 限公司（以下简称"福瑞达"或"公司"）的委托，指派本所律师林泽若明、张 灵君（以下简称"本所律师"）出席福瑞达 2026 年第一次临时股东会（以下简 称"本次股东会"），并出具本法律意见书。 2026 年第一次临时股东会 之 法律意见书 济南市龙奥西路 1 号银丰财富广场 C 座 19、20、25 层 邮编：250014 19th-20th、25thFloor,BlockC,YinfengFortunePlaza,No.1Long'aoWestRoad,Jinan 电话/Tel:+8653186112118 传真/Fax:+8653186110945 网址/Website:http://www.grandall.com.cn 为出具本法律意见书，本所律师出席了本次股东会，并 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The report highlights the successful IPO of Shaanxi Tourism, which leverages its rich tourism resources and strong operational experience to build competitive advantages through a combination of performance-driven tourism, cable car operations, and dining services [22][24][34] - The report emphasizes the resilience of the cultural tourism industry amid ongoing trends to expand domestic demand and promote consumption, suggesting that Shaanxi Tourism's future growth will be supported by new performance projects and cable car capacity upgrades [36] Summary by Sections Retail and Social Services Market Review - The retail and social services indices rose by 4.23% and 4.71% respectively during the week of January 5 to January 9, 2026, with the Shanghai Composite Index increasing by 3.82% [12][14] - Among the sub-sectors, the supermarket segment showed the highest growth, with an increase of 8.18% year-to-date [15][17] Industry Dynamics: Shaanxi Tourism - Shaanxi Tourism, a leading regional tourism company, successfully listed on the Shanghai Stock Exchange on January 6, 2026, becoming the first A-share listed company of the year [22] - The company reported significant revenue contributions from its tourism performance and cable car operations, with a net profit margin and gross profit margin remaining high post-pandemic [24][27] - Revenue breakdown for the first half of 2025 shows that tourism performance accounted for 60.2%, cable car operations for 35.8%, and dining services for 4.0% [24] Investment Recommendations - The report recommends focusing on high-end gold and fashion jewelry brands, highlighting companies like Chow Tai Fook and Chao Hong Ji, which are expected to benefit from market trends [39] - It also suggests monitoring offline retail companies adapting to market changes and AI-enabled cross-border e-commerce leaders, with specific recommendations for Yonghui Supermarket and Aiying Room [39] - In the cosmetics sector, the report emphasizes brands that capture emotional value and innovate with safe ingredients, recommending companies like Mao Ge Ping and Proya [40]

Market Overview - The cosmetics sector increased by 1.29% on January 9, with Shuiyang Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 4120.43, up 0.92%, while the Shenzhen Component Index closed at 14120.15, up 1.15% [1] Individual Stock Performance - Shuiyang Co., Ltd. (300740) closed at 25.65, up 5.90% with a trading volume of 223,500 shares and a transaction value of 561 million yuan [1] - Qingsong Co., Ltd. (300132) closed at 8.70, up 2.47% with a trading volume of 253,700 shares [1] - Beitaini (300957) closed at 41.20, up 1.85% with a trading volume of 163,500 shares and a transaction value of 261 million yuan [1] - Other notable stocks include Furuida (600223) at 7.53 (+1.76%), Jiaheng Jiahua (300955) at 39.89 (+1.68%), and Huaye Fragrance (300886) at 26.64 (+1.06%) [1] Capital Flow Analysis - The cosmetics sector experienced a net outflow of 31.72 million yuan from institutional investors and 34.45 million yuan from speculative funds, while retail investors saw a net inflow of 66.18 million yuan [2] - Individual stock capital flows indicate that Qindao Jinwang (002094) had a net inflow of 13.96 million yuan from institutional investors, while it faced a net outflow of 1.23 million yuan from speculative funds [3] - Other stocks like Qingsong Co., Ltd. (300132) and Beitaini (300957) also showed mixed capital flows, with varying levels of net inflows and outflows from different investor categories [3]

Group 1 - The Shanghai Composite Index rose by 0.05% on January 7, with 17 industries experiencing gains, led by the comprehensive and coal sectors, which increased by 3.86% and 2.47% respectively [1] - The oil and petrochemical and non-bank financial sectors saw the largest declines, with decreases of 1.73% and 1.13% respectively [1] - The beauty and personal care industry ranked third in terms of decline for the day, falling by 1.03% [2] Group 2 - The beauty and personal care industry experienced a net outflow of 73.58 million yuan, with 29 stocks in the sector, of which only 4 rose while 24 fell [2] - The top three stocks with the largest net outflows in the beauty and personal care sector were Qingdao Kingking, Aimeike, and Furida, with outflows of 43.47 million yuan, 21.05 million yuan, and 15.05 million yuan respectively [2][3] - The stock with the highest net inflow was Shuiyang Co., with an inflow of 18.80 million yuan, followed by Perleya and Zhongshun Jierou with inflows of 10.12 million yuan and 9.53 million yuan respectively [2][3]

Group 1 - The cosmetics sector experienced a decline of 0.93% on January 7, with Jiaheng Jiahua leading the drop [1] - The Shanghai Composite Index closed at 4085.77, up 0.05%, while the Shenzhen Component Index closed at 14030.56, up 0.06% [1] - Key individual stock performances in the cosmetics sector included Bawei Co. up 0.85% and Jiaheng Jiahua down 4.96% [2] Group 2 - The net outflow of main funds in the cosmetics sector was 57.67 million yuan, while retail investors saw a net inflow of 39.72 million yuan [2] - The stock with the highest main fund inflow was Shuiyang Co. with 27.77 million yuan, while Jiaheng Jiahua had a significant outflow of 32.2 million yuan [3] - Retail investors showed a negative net flow in several stocks, including Shanghai Jahwa and Kesheng Co. [3]

Group 1 - The cosmetics sector experienced a rise of 0.46% on January 6, with Lafang Jiahua leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up by 1.5%, while the Shenzhen Component Index closed at 14022.55, up by 1.4% [1] - Lafang Jiahua's closing price was 20.34, reflecting a 1.90% increase, with a trading volume of 52,800 shares and a transaction value of 108 million yuan [1] Group 2 - The cosmetics sector saw a net outflow of 81.97 million yuan from institutional investors, while retail investors had a net inflow of 67.35 million yuan [2] - The trading data indicates that major stocks like Shanghai Jahwa and Lafang Jiahua had mixed net inflows and outflows from different investor types [3] - Shanghai Jahwa had a net inflow of 9.64 million yuan from institutional investors, while it faced outflows from retail investors [3]

Core Insights - Hyaluronic acid, once costly and referred to as "liquid gold," has seen significant technological advancements in production, particularly by the company Furuida, which has transitioned from animal extraction to microbial fermentation and synthetic biology [1][4] - Furuida has become a key player in the global hyaluronic acid market, controlling 70% of the raw material supply, and is recognized as a driving force behind the industry's innovation and upgrade [1][4] Technological Breakthroughs - Furuida emphasizes that raw material innovation is crucial for industry upgrades, positioning it as the foundation for pharmaceutical and cosmetic development [4] - The company has achieved a significant milestone by being recognized as the "global pioneer in biosynthetic royal jelly acid," marking a transition from theoretical validation to industrial application [4] - Furuida's collaboration with Qilu University of Technology has led to the successful development of a microbial cell factory for efficient production of royal jelly acid, shifting from reliance on scarce natural resources to sustainable manufacturing [4] Industry Expansion - Furuida is actively expanding its raw material portfolio, including the acquisition of international hyaluronic acid leaders and entering the fragrance sector through strategic mergers [8] - The company has established a collaborative matrix of six subsidiaries focused on cosmetic and pharmaceutical raw material development, enhancing its global competitive advantage [8] - Furuida has achieved key regulatory milestones, including the registration of Class III medical device raw materials and the approval of A-class raw materials for pharmaceuticals, validating its R&D capabilities and quality management [8][9] Product Development and Market Strategy - Furuida is implementing a "5+N" brand development strategy, focusing on various skincare and medical fields, and has successfully launched several well-known brands [10] - The company has created a comprehensive product matrix in the medical health sector, maintaining competitive market positions in ophthalmology, orthopedics, dermatology, and gynecology [10] Talent and Innovation - Continuous R&D investment and a systematic talent strategy are central to Furuida's innovation in raw materials and products [13] - The establishment of a provincial-level research platform and partnerships with universities enhances Furuida's R&D capabilities and talent cultivation [13][14] - Furuida's products are now exported to 79 countries, supported by various international certifications, establishing a strong foundation for global market entry [14]

Core Insights - The article discusses the competitive landscape of the hair medical industry in China, highlighting key players and market dynamics [1][5]. Group 1: Competitive Landscape - The Chinese hair medical industry features various competitive factions, with companies like Yonghe Medical, Damaik, and Qingyi focusing on hair transplant medical services, while SanSheng Pharmaceutical, Zhendong Pharmaceutical, and Xianju Pharmaceutical are involved in medical nurturing services [1]. - In the hair transplant sector, the first tier consists of leading national chain brands such as Yonghe Medical, Bilian Sheng, and Damaik, which collectively hold a significant market share and possess nationwide direct chain layouts, mature technology systems, and strong brand recognition [1]. Group 2: Hair Growth Pharmaceuticals - In the hair growth pharmaceuticals market, the first tier includes SanSheng Pharmaceutical, Zhendong Pharmaceutical, and Merck, with the former two holding major shares in the minoxidil market, while Merck is recognized as the original manufacturer of finasteride [5]. - The second tier comprises Xianju Pharmaceutical, Kang En Bei, and Xiamen Meishang Pharmaceutical, which have accelerated the launch of minoxidil and finasteride products in recent years, gaining notable market recognition [5]. Group 3: Sales Performance - In the online pharmacy sector, Zhejiang SanSheng's minoxidil tincture product achieved sales exceeding 1 billion yuan, while Zhendong Anxin's minoxidil lotion surpassed 300 million yuan in sales, and SanSheng's minoxidil foam also exceeded 100 million yuan [9]. - In the offline market during the first quarter of 2025, Zhejiang SanSheng's minoxidil tincture and Zhendong Anxin's minoxidil lotion both recorded sales above 20 million yuan, with market shares of 50.61% and 38.82%, respectively [10]. - The sales ranking for minoxidil products shows Zhejiang SanSheng's minoxidil tincture leading with over 34 million yuan in sales (50.61% market share), followed by Zhendong Anxin's minoxidil lotion with over 26 million yuan (38.82% market share) [11].

Core Viewpoint - Furuida, a state-controlled listed company under Lushang Group, is recognized for its innovation-driven industrial upgrades in the pharmaceutical and cosmetics sectors, having formed a collaborative innovation consortium and achieved significant technological breakthroughs [1][3]. Group 1: Innovation and Collaboration - Furuida has been a leader in the hyaluronic acid industry for over 30 years, addressing challenges such as limited core technologies and low competitiveness of high-value products through open collaboration [3]. - The company has established the "Shandong Synthetic Biology and Green Manufacturing Innovation Consortium," integrating top universities and research institutions to tackle common technological challenges in cutting-edge fields like cell factories and green catalysis [3]. - Furuida's research team has developed a nanocrystal/bioadhesive transmembrane delivery technology that resolves critical issues in drug absorption and targeting, resulting in 29 national invention patents and the launch of 33 new drug products, generating an annual output value exceeding 1 billion yuan [4]. Group 2: Ecosystem and Market Position - Furuida promotes a "four-chain" integration model to bridge gaps between talent, education, innovation, and industry, enhancing the flow of innovation elements [6]. - The company has implemented a collaborative investment and shared outcome model, creating a full chain from raw material research to end products, and has initiated the "Hyaluronic Acid+" industry ecosystem plan, successfully incubating 19 new brands [6]. - Since the 14th Five-Year Plan, Furuida has solidified its leading position in the hyaluronic acid sector, establishing a research cluster with 4 national and 17 provincial platforms, and has undertaken over 30 major scientific projects, accumulating nearly 400 authorized patents [6].

Investment Rating - The report maintains a "Positive" investment rating for the beauty and personal care industry, specifically focusing on PDRN applications [6]. Core Insights - The report highlights that PDRN (Polydeoxyribonucleotide) is expected to unleash stronger commercial potential due to increasing registrations and search metrics. The extraction of PDRN is transitioning from animal sources to microbial fermentation and synthetic biology, laying a solid foundation for accelerated applications in the medical beauty and skincare sectors [3][4]. - The report emphasizes that domestic beauty companies are likely to redefine the value boundaries of PDRN, with leading firms accelerating their strategies in this competitive landscape [3][4]. Summary by Sections PDRN Overview - PDRN, derived from salmon and other sources, has a high similarity to human DNA (98%) and is known for its skin repair and cell regeneration properties. Its historical development spans from the 15th century to its current applications in medical aesthetics and cosmetics [8][13][19]. Market Growth Potential - The PDRN market is projected to grow significantly, with estimates indicating an increase from USD 0.72 billion in 2024 to USD 8.55 billion by 2031, reflecting a CAGR of 43%. The demand for anti-aging products is a core driver of this growth [8][30]. Competitive Landscape - Domestic companies are actively entering the PDRN medical and skincare sectors, with significant advancements in extraction technologies. Companies like Huaxi Biological and Lepu Medical are leading the charge in developing PDRN-based products [8][30][34]. Key Mechanisms and Benefits - PDRN operates through two main mechanisms: acting as an agonist for the adenosine A2A receptor to suppress inflammation and providing nucleotides for DNA synthesis, thus promoting cell regeneration and tissue repair [34][36]. - The primary benefits of PDRN include skin repair, anti-inflammatory effects, and anti-aging properties, making it suitable for various cosmetic and medical applications [34][39].